Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business From Novasep pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
02.16.21 Do These Recent Warning Letters Signal A Shift In FDA Enforcement?
Upload an image of your current/old CO2 incubator for a chance to win a brand new FREE NuAire In-Vitrocell NU-5810 CO2 Incubator. Other prizes include a monthly drawing for a branded Under Armour backpack, Camelbak metal water bottle, and various gift cards. All entries will receive a FREE NU-1582 CO2 Incubator Castered Platform with your next NuAire CO2 Incubator purchase. Contest valid until 7/31/2021. Restrictions apply.
Featured Editorial
By Barbara Unger, Unger Consulting Inc.
The FDA posted two unique warning letters that all pharmaceutical and API firms, regardless of their product category, should consider and evaluate. These first-of-a-kind warning letters represent a renewed emphasis on both alternatives to on-site inspections and the importance of purchasing controls and supplier management.
Data Bridge Market Research recently added “
Clinical Trial Supplies Market by manufacturers, regions, type and application, forecast to 2028” in his database. This research report focus on complete assessment of market and contains future trend, growth factors, attentive opinions, facts, historical data, statistically supported and industry-validated market data. Environmental concerns & regulatory guidelines regarding release of effluents through different industries.
Clinical Trial Supplies Market comprehensive coverage of underlying economic and technological factors under key trend analysis.
The clinical trial supplies market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.8% in the forecast period of 2020 to 2027 and is expected to reach USD 4,843.55 million by 2027. The rising demand in clinical trials worldwide is the factor leading the growth of the clinical
Global Proteomics Partnering Terms and Agreements Analysis Report 2020
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Jan 21 2021 Read 877 Times
Thermo Fisher Scientific Inc and Groupe Novasep SAS have announced that Thermo Fisher has completed the acquisition of Henogen SA, Novasep’s viral vector manufacturing business in Belgium for approximately €725 million in cash.
Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Novasep’s viral vector business offers more than 7,000 m2 of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of €80 million (or approximately $95 million).